

Claims

1. A composition for use in alleviating menopause-associated symptoms, wherein said composition comprises an estetrol component and wherein said composition is administered at a daily amount equivalent to from about 15 mg to about 25 mg of estetrol.
- 5 2. The composition for use of Claim 1 wherein a second composition comprising a progestogenic component is additionally used.
3. The composition for use of Claim 2 wherein said progestogenic component is selected from
10 drospirenone, progesterone and dydrogesterone.
4. The composition for use of Claim 2 wherein progesterone is administered at a daily dose of from 50 mg to 200 mg.
- 15 5. The composition for use of Claim 1 wherein a second composition comprising bazedoxifene is additionally used.
6. A composition for use according to any one of Claims 2-5 wherein said second composition comprising a progestogenic component or bazedoxifene is the same as the composition
20 comprising the estetrol component.
7. A composition for use according to any one of Claims 1-6 wherein the estetrol component is estetrol, preferably estetrol monohydrate.
- 25 8. A composition for use according to any of the preceding claims wherein the composition is formulated as an oral dosage unit.
9. The composition for use according to Claim 8 wherein the oral dosage unit is formulated to correspond to a daily dosage unit.
- 30 10. A packaging unit comprising at least 21, preferably at least 28, containers for holding separately packaged and individually removable daily solid oral dosage forms, wherein each container comprises at least one daily solid oral dosage form comprising from about 15 mg to about 25 mg of estetrol.
- 35 11. The packaging unit according to Claim 10, wherein the packaging unit additionally comprises at least 10, preferably 12, more preferably 14, additional containers for holding separately packaged and individually removable daily, preferably solid, oral dosage forms, wherein each

additional container comprises at least one daily, preferably solid, oral dosage form comprising a progestogenic component.

5 12. The packaging unit according to Claim 11, wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone.

13. The packaging unit according to Claim 12, wherein said progestogenic component is progesterone and wherein each said additional containers comprises at least one daily oral dosage form comprising about 200 mg of progesterone.

10

14. The packaging unit according to Claim 10, wherein the packaging unit additionally comprises the same number of additional containers for holding separately packaged and individually removable daily, preferably solid, oral dosage forms, wherein each additional container comprises at least one daily, preferably solid, oral dosage form comprising a progestogenic component, preferably wherein said progestogenic component is selected from drospirenone, 15 progesterone and dydrogesterone, even more preferably wherein said progestogenic component is progesterone and wherein said additional container comprises at least one daily oral dosage form comprising about 100 mg of progesterone.

20 15. The packaging unit according to Claim 10, wherein each said daily solid oral dosage form additionally comprises a progestogenic component.

25